Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VIRTUOSE: Sildenafil for PAD with Intermittent Claudication
NCT03686306Phase 3Active, not recruiting
- Sponsor
- CHU Rennes
- Start
- Nov 2021
- Primary completion
- Nov 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of ASP-001 in Peripheral Arterial Disease (PAD) (2 arms), sponsored by CHU Rennes. Primary endpoint: Absolute Claudication Distance at 24 weeks. Started Nov 2021; status: active, not recruiting.
02
Drugs
ASP-001
03
Conditions
Peripheral Arterial Disease (PAD)
Beyond the preview
Go deeper on NCT03686306.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03686306.